<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02327351</url>
  </required_header>
  <id_info>
    <org_study_id>TCRabPID-2012</org_study_id>
    <nct_id>NCT02327351</nct_id>
  </id_info>
  <brief_title>TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID</brief_title>
  <official_title>Phase II/III Study of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated and Haploidentical Donors After TCR Alfa Beta Negative Selection in Pediatric Patients With Primary Immunodeficiency Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment Study to assess of safety and efficiency of T cells receptor (TCR) alfa beta
      depleted graft for hematopoietic stem cell transplantation (HSCT) from haploidentical and
      unrelated donors in patients with primary immunodeficiency diseases
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infections, graft versus host diseases (GVHD) and associated morbidity and mortality remains
      significant problems after unrelated and haploidentical hematopoietic stem sell
      transplantation (HSCT) in patients with primary immunodeficiency diseases (PID). In this
      study the hypothesis is that the transplantation of TCR alfa beta depleted peripheral blood
      stem cells (PBSC) would offers advantages over the use of positively selected CD34+ stem
      cells in haploidentical HSCT and non-manipulated graft in unrelated HSCT.

      The purpose of this study is to evaluate the safety and efficiency of the selective infusion
      of TCR alfa beta T cell depleted graft in pediatric patients with PID receiving HSCT from
      haploidentical and unrelated donors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 24 months after transplantation</time_frame>
    <description>The OS probability compared with cohort of historical control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transplant related mortality (TRM)</measure>
    <time_frame>up to 24 months after transplantation</time_frame>
    <description>The TRM probability compared with cohort of historical control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute graft versus host diseases (аGVHD)</measure>
    <time_frame>up to 12 months after transplantation</time_frame>
    <description>Cumulative incidence and severity of II-IV grade of aGVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic graft versus host diseases (cGVHD)</measure>
    <time_frame>up to 24 months after transplantation</time_frame>
    <description>Cumulative incidence and severity of cGVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular Immunological reconstitution by laboratory evaluations</measure>
    <time_frame>up to 24 months after transplantation</time_frame>
    <description>The recovery of different lymphocyte's subpopulation (CD3+; CD3+CD45RA+CD197; CD19+; CD4+; CD8+; TCR alfa beta; TCR gamma delta)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with full/mixed donor chimerism</measure>
    <time_frame>up to 12 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral infections after transplant</measure>
    <time_frame>up to 12 months after transplantation</time_frame>
    <description>Cumulative incidence on CMV and EBV reactivation/diseases</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Primary Immune Deficiency Disorder</condition>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>TCR alfa beta depletion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological: TCR alfa beta T cell depletion</intervention_name>
    <arm_group_label>TCR alfa beta depletion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged ≥ 1 months and &lt; 19 years

          -  Patients diagnosed with Primary Immunodeficiency Diseases eligible for an allogeneic
             transplantation and lacking a related HLA-matched donor

          -  Lansky/Karnofsky score &gt; 40, WHO &gt; 4

          -  Signed written informed consent

        Exclusion Criteria:

          -  Dysfunction of liver (ALT/AST &gt; 5 times normal value, or bilirubin &gt; 3 times normal
             value), or of renal function (creatinine clearance &lt; 30 ml / min)

          -  Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive
             heart failure or left ventricular ejection fraction &lt;40%)

          -  Serious concurrent uncontrolled medical disorder

          -  Pregnant or breast feeding female patient

          -  Lack of parents' informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexei Maschan, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Dmitry Rogachev Federal Research and Clinical Centre of Paediatric Haematology, Oncology and Immunology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dmitry Balashov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dmitry Rogachev Federal Research and Clinical Centre of Paediatric Haematology, Oncology and Immunology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dmitry Balashov, MD, PhD</last_name>
    <phone>+7(495)287-6570</phone>
    <phone_ext>6534</phone_ext>
    <email>bala8@yandex.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Maschan, Professor</last_name>
    <phone>+7(926)651-2145</phone>
    <email>mmaschan@yandex.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dmitry Rogachev Federal Research and Clinical Centre of Paediatric Haematology, Oncology and Immunology</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitry Balashov, MD, PhD</last_name>
      <phone>+7(495)287-6570</phone>
      <phone_ext>6534</phone_ext>
      <email>bala8@yandex.ru</email>
    </contact>
    <contact_backup>
      <last_name>Michael Maschan, Professor</last_name>
      <email>mmaschan@yandex.ru</email>
    </contact_backup>
    <investigator>
      <last_name>Dmitry Balashov, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Maschan, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Shcherbina, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Laberko, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yulia Skvortsova, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2014</study_first_posted>
  <last_update_submitted>July 23, 2016</last_update_submitted>
  <last_update_submitted_qc>July 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

